The long-term outlook (5-8% revenue CAGR, 8.5-11.5% EPS CAGR) is in line with the company's historical performance and provides a clear framework for valuation. Monitor upcoming quarterly results for execution against the 2026 guidance and any updates on M&A pipeline or LaunchPad savings. The stock has outperformed the S&P 500 Healthcare index since the prior Investor Day (144% vs 88% TSR), suggesting elevated expectations are already priced in.
Price Chart
Executive Summary
Labcorp held its 2026 Investor Day, reaffirming full-year 2026 guidance and providing a long-term outlook through 2029. The company targets 5%-8% compound annual revenue growth and 8.5%-11.5% adjusted EPS CAGR, driven by specialty diagnostics, technology, and M&A. The filing is a routine strategic update with no new financial data beyond previously issued guidance.
Key Facts
- Reaffirmed FY2026 guidance: Enterprise revenue $14.71B-$14.83B (+5.4% to +6.3% YoY), Adjusted EPS $18.10-$18.55 (+10.1% to +12.8% YoY), Free Cash Flow $1.24B-$1.36B.
- Long-term outlook (2026-2029): 5%-8% revenue CAGR, 75-150 bps adjusted operating margin expansion by end of 2029, 8.5%-11.5% adjusted EPS CAGR.
- Organic revenue growth target of 3.5%-5.5% CAGR, with M&A contributing an additional 1.5%-2.5% CAGR.
- Diagnostics segment revenue grew from $9.4B in 2023 to $11.5B at 2026 guidance midpoint (7% CAGR).
- Biopharma Laboratory Services revenue grew from $2.8B in 2023 to $3.3B at 2026 guidance midpoint (6% CAGR).
- Capital deployment from 2023-2025: $6.1B total, with $3.7B reinvested in the business ($1.4B CapEx, $2.3B M&A) and $2.4B returned to shareholders ($0.7B dividends, $1.7B share repurchases).
- LaunchPad productivity savings targeted at $125M-$150M per year.
- Financial leverage target: 2.5x to 3.0x gross debt to TTM adjusted EBITDA.
- Specialty diagnostics (oncology, neurology, autoimmune, women's health) generating $2B in annual revenue with strong growth rates.
- Over 30 M&A deals from 2023-2025 contributed $900M in acquired revenue.
Financial Impact
Reaffirmed FY2026 guidance: Enterprise revenue $14.71B-$14.83B, Adjusted EPS $18.10-$18.55, Free Cash Flow $1.24B-$1.36B. Long-term targets: 5%-8% revenue CAGR, 8.5%-11.5% adjusted EPS CAGR through 2029.
Risk Factors
- Potential impact of PAMA (Protecting Access to Medicare Act) on diagnostics reimbursement.
- Foreign exchange headwinds (0.4% impact on enterprise revenue, 1.5% on BLS).
- Execution risk on M&A integration and achieving targeted 1.5%-2.5% acquisition revenue CAGR.
- Macroeconomic pressures and inflation affecting healthcare utilization.
- Competition from hospital labs and other independent lab providers.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000920148-26-000201 |
| Document: formpr091026ex991investord.htm | 0000920148-26-000201 |
| Document: lh-20260910.htm | 0000920148-26-000201 |
| Document: 0000920148-26-000201-index-headers.html | 0000920148-26-000201 |
| Document: 0000920148-26-000201-index.html | 0000920148-26-000201 |
| Document: 0000920148-26-000201.txt | 0000920148-26-000201 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 21d ago | 8-K | $311.54 $320.71 | ▲ +2.94% | ▲ +3.16% | $306.38 (−1.66%) |
Aug 28, 2026 5w ago | 8-K | $335.11 $326.89 | ▼ −2.45% | ▼ −2.56% | $306.38 (−8.57%) |
Aug 18, 2026 6w ago | Insider Cluster | $322.18 $337.68 | ▲ +4.81% | ▲ +5.01% | $306.38 (−4.90%) |
Aug 17, 2026 6w ago | 8-K | $323.34 $339.34 | ▲ +4.95% | ▲ +6.14% | $306.38 (−5.25%) |
Aug 14, 2026 7w ago | 8-K | $318.13 $336.34 | ▲ +5.72% | ▲ +7.09% | $306.38 (−3.69%) |
Aug 12, 2026 7w ago | Insider Cluster | $323.48 $330.44 | ▲ +2.15% | ▲ +2.60% | $306.38 (−5.29%) |
Aug 6, 2026 8w ago | Insider Cluster | $316.53 $322.59 | ▲ +1.91% | ▲ +0.70% | $306.38 (−3.21%) |
Jul 30, 2026 9w ago | 8-K | $315.53 $316.53 | ▲ +0.32% | ▼ −3.31% | $306.38 (−2.90%) |
Jul 10, 2026 12w ago | 8-K | $276.81 $281.94 | ▲ +1.85% | ▲ +2.41% | $306.38 (+10.68%) |
Jun 30, 2026 13w ago | 8-K | $283.88 $283.86 | ▼ −0.01% | ▼ −0.27% | $306.38 (+7.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access